Genitourinary Cancer

Few centers have our breadth of treatment options for patients. A key strength of our group is the ability, expertise, and desire to individualize treatment strategy to the patient. As an early adopter and developer of radiation technologies, we offer many treatment modalities, including brachytherapy (radioactive seed implant), stereotactic body radiotherapy (SBRT), image-guided intensity modulated radiotherapy (IG-IMRT), volumetric modulated arc therapy (VMAT), and more.

GU Clinical Trials

As one of the top academic medical centers in the country and the only NCI-designated cancer center in North Texas, we lead and participate in a number of clinical trials aimed at improving the outcomes of patients with cancer. Our Department enrolls approximately 200 new patients in clinical trials each year. 

Clinical trials are critical in developing new therapies for cancer and can mean having access to new medication, groundbreaking research, and additional clinical care. Our clinical trials team is comprised of radiation oncologists, radiation biologists, clinical research coordinators, quality assurance coordinators, and clinical data specialists.

Therapeutic

Prostate Cancer

• Phase II randomized placebo-controlled double-blind study of salvage radiation therapy (SRT) plus placebo versus SRT plus enzalutamide in men with high-risk PSA-recurrent prostate cancer after radical prostatectomy (SALV-ENZA). (STU 122016-067)
• Prostate oncologic therapy while ensuring neurovascular conservation (POTEN-C): a phase II randomized controlled trial of stereotactic ablative body radiotherapy (SABR) with or without neurovascular sparing for erectile function preservation in localized prostate cancer. Learn more about the POTEN-C trial. (STU 092017-018)
• A phase I/II trial of focal salvage high-dose-rate brachytherapy for locally recurrent prostate cancer in patients treated with prior radiotherapy. (STU 2019-1596: F-SHARP)
• A phase II randomized trial of Radium-223 and SABR Versus SABR for oligometastatic prostate cancers. (STU 2020-0329: RAVENS)
• A multi-center study of androgen suppression with Abiraterone aCetate, LEuprolide, PARP Inhibition and Stereotactic Body Radiotherapy (ASCLEPIuS). A phase 1/2 trial in high-risk or node-positive prostate cancer. (STU 022011-213: ASCLEPIuS)
• Parallel phase III randomized trial of genomic-risk stratified unfavorable intermediate risk prostate cancer: de-intensification and intensification clinical trial evaluation (Guidance). (STU 2021-1091: NRG-GU010) For more information and videos on this trial, please see below.
• Using the UroLift System with stereotactic ablative body radiotherapy for men with prostate cancer and benign prostatic hyperplasia (BPH): a phase I safety trial. (STU 2022-0261)

Renal Cancer

• Safety lead-in phase II trial of neo-adjuvant SABR for IVC tumor thrombus in newly diagnosed RCC. (STU 022015-058)
• IVC thrombus safety lead-in phase II trial of neo-adjuvant SABR for IVC tumor thrombus in newly diagnosed RCC. (STU 022015-058)

Radical Prostatectomy

• Phase II-III trial of adjuvant radiotherapy and androgen deprivation following radical prostatectomy with or without adjuvant docetaxel. (STU 022017-032)

Non-Therapeutic

Prostate

• Post-market registry to evaluate toxicity and clinical outcomes following the use of temporary hydrogel rectal spacer in the treatment of localized prostate cancer with radiation therapy. (STU 062017-067)

If you’re interested in a clinical trial, please talk to your doctor.

Learn more about clinical trials.